Carl H. June

California University of Pennsylvania — United States

Medicine · Health Sciences

177h-index143.1kcitations1.4kworks16.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(925), Immune Cell Function and Interaction(346), Immunotherapy and Immune Responses(283), Virus-based gene therapy research(198), T-cell and B-cell Immunology(191)

Publications1.4k total

Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.
2026Open Access
Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy
Proceedings of the National Academy of Sciences·2025Open Access
CAR T cells targeting CCR4 selectively deplete human Tregs ex vivo and in vivo
Blood Advances·2025Open Access
DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity
Molecular Therapy·2025Open Access
Supplementary Figure 7 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 4 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 1 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 2 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 5 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 3 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Table 1 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Figure 6 from Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function
2025Open Access
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors
2025Open Access
Supplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
2025Open Access
IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy
Immunity·2025· 2 cited
Viral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor
Blood Immunology & Cellular Therapy·2025Open Access
Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia
Blood·2025
Single-day non-activated IL-18-armed CAR T cells with enhanced persistence and durable efficacy
Blood·2025Open Access
Metabolic conditioning for enhanced CAR T cell function
Blood·2025
Lipid nanoparticle-mediated epitope editing in human HSPCs enables resistance to CD45-directed CAR-T cell therapy
Blood·2025Open Access
page 1 of 71Next →

Frequent Co-authors

Bruce L. Levine(25), Simon F. Lacey(14), J. Joseph Melenhorst(13), Michael Kalos(11), Stephan A. Grupp(9), David L. Porter(8), James L. Riley(8), Michael C. Milone(7), Gabriela Plesa(7), Marcela V. Maus(7), Wei‐Ting Hwang(7), Joseph A. Fraietta(7), Irina Kulikovskaya(7), Anne Chew(6), Minnal Gupta(6), Regina M. Young(6), Edward A. Stadtmauer(6), Yangbing Zhao(6), Noelle V. Frey(5), Zhaohui Zheng(5)